CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a flow business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.24B, above the global median of $1.15B
- PositionReturn on equity is 25%, higher than 95% of its Medical Devices peers (median 3%)
- Interpretations12 currently firing — 12
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a flow business
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.82%
Annual Rate
USD 0.80Paid quarterly
Payout Ratio
38.8%Sustainable
Consecutive Growth
1 yr
Paying Dividends
5 yr
Payback Period
82.1 yr
Last Ex-Dividend
May 15, 2026
Last Payment
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.24BUSDvs all stocks (USD)
Trailing P/E
53.02xvs Medical Devices peers
Revenue (TTM)
86.28MUSDvs all stocks (USD)
Profit Margin
27.37%vs Medical Devices peers
Beta
0.9100xvs all stocks
52-Week Change
72.68%vs all stocks
Forward Annual Dividend Yield
0.82%vs all stocks
Market Capitalization
1.24BUSDvs all stocks (USD)
Enterprise Value
1.18BUSDvs all stocks (USD)
Trailing P/E
53.02xvs Medical Devices peers
Forward P/E
41.20xvs Medical Devices peers
PEG Ratio
2.18xvs Medical Devices peers
Price to Sales (TTM)
14.38xvs Medical Devices peers
Price to Book (MRQ)
12.59xvs Medical Devices peers
Enterprise to Revenue
13.72xvs Medical Devices peers
Enterprise to EBITDA
40.30xvs Medical Devices peers
Gross Margin
76.50%vs Medical Devices peers
Profit Margin
27.37%vs Medical Devices peers
Operating Margin
32.93%vs Medical Devices peers
Return on Assets (TTM)
16.17%vs Medical Devices peers
Return on Equity (TTM)
25.04%vs Medical Devices peers
Revenue (TTM)
86.28MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.77USDUpdated Jul 19, 2026Quarterly Revenue Growth
12.60%vs Medical Devices peers
Gross Profit (TTM)
66.30MUSDvs all stocks (USD)
EBITDA (TTM)
29.38MUSDvs all stocks (USD)
Net Income (TTM)
23.61MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
24.10%vs Medical Devices peers
Operating Cash Flow (TTM)
28.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
15.16MUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.8000USDUpdated Jul 19, 2026Forward Annual Dividend Yield
0.82%vs all stocks
Trailing Annual Dividend Rate
1.07USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
1.10%vs all stocks
Payout Ratio
38.80%vs Medical Devices peers
Revenue
83.81MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
19.49MUSDFY2025 · Dec 31, 2025Gross Profit
64.32MUSDFY2025 · Dec 31, 2025Operating Income
26.15MUSDvs all stocks (USD)
Pre-tax Income
28.36MUSDFY2025 · Dec 31, 2025Income Tax Expense
5.88MUSDFY2025 · Dec 31, 2025Net Income
22.48MUSDFY2025 · Dec 31, 2025EBIT
26.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
27.11MUSDFY2025 · Dec 31, 2025Research & Development
2.98MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
35.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.01MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.77USDFY2025 · Dec 31, 2025EPS (Diluted)
1.75USDFY2025 · Dec 31, 2025Basic Shares Outstanding
12.72MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
12.72MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
22.48MUSDFY2025 · Dec 31, 2025Operating Cash Flow
26.24MUSDFY2025 · Dec 31, 2025Free Cash Flow
18.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
51.16MUSDFY2025 · Dec 31, 2025Income Tax Paid
3.92MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
22.48MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.17MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
2.73MUSDFY2025 · Dec 31, 2025Stock-based Compensation
2.92MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-76.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
55.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-7.76MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.76MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-15.04MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.56MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.60MUSDFY2025 · Dec 31, 2025Shares Outstanding
12.78MSharesUpdated Jul 19, 2026Float Shares
8.33MSharesUpdated Jul 19, 2026Shares Short
685.97KSharesUpdated Jul 19, 2026Short Ratio
4.59daysvs all stocks
Short % of Shares Outstanding
8.28%vs all stocks
% Held by Insiders
35.20%vs all stocks
% Held by Institutions
61.25%vs all stocks
Total Cash (MRQ)
56.37MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.41USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Medical Devices peers
Current Ratio (MRQ)
7.13xvs Medical Devices peers
Book Value per Share (MRQ)
7.71USDUpdated Jul 19, 2026Total Assets
108.78MUSDvs all stocks (USD)
Total Current Assets
81.20MUSDFY2025 · Dec 31, 2025Total Liabilities
14.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
27.57MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.98MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
51.16MUSDFY2025 · Dec 31, 2025Accounts Receivable
13.67MUSDFY2025 · Dec 31, 2025Inventory
11.62MUSDFY2025 · Dec 31, 2025Accounts Payable
1.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.87MUSDFY2025 · Dec 31, 2025Other Current Liabilities
313.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
64.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
94.62MUSDvs all stocks (USD)
52-Week Low
55.11USDUpdated Jul 19, 202652-Week High
107.90USDUpdated Jul 19, 202652-Week Change
72.68%vs all stocks
Beta
0.9100xvs all stocks
50-Day MA
92.71USDUpdated Jul 19, 2026200-Day MA
92.40USDUpdated Jul 19, 2026Avg 10-Day Volume
135.84KSharesUpdated Jul 19, 2026Avg 30-Day Volume
146.48KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
1.83USDUpdated Jul 19, 2026Other Income / Expense
205.00KUSDFY2025 · Dec 31, 202512 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 25%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.25Industry median: 0.03Industry P95: 0.17Peers compared: 102
Return on assets is 16.2%, higher than 95% of its Medical Devices peers (median 1.9%)Significant
Return on assets: 0.16Industry median: 0.02Industry P95: 0.12Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Structural Tensions
Most companies in its industry are production businesses; this one is a flow businessSignificant
Industry peers: 174Share on the common pattern %: 98.00
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.63
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.24B, above the global median of $1.15BNotable
Market cap (USD): 1,240,337,873Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
AdaptHealth Corp.
Tier 1FlowApproval-Gated PipelineInterfaceProduction
Hyundai Movex Co., Ltd.
Tier 1FlowApproval-Gated PipelineProductionRisk
Viemed Healthcare Inc.
Tier 1FlowApproval-Gated PipelineProductionRule
Lumexa Imaging Holdings, Inc.
Tier 2FlowApproval-Gated PipelineInterfaceRule
Nanjing Pharmaceutical Co., Ltd.
Tier 2FlowApproval-Gated PipelineInterfaceRule
Dimed S.A. Distribuidora de Medicamentos
Tier 2FlowApproval-Gated PipelineInterfaceRule
Hyundai Glovis Co., Ltd.
Tier 3FlowThroughput-Bound ConversionProductionRisk
Tianjin Capital Environmental Protection Group Co., Ltd.
Tier 3FlowRegulated Return InfrastructureProductionRule
New Guomai Digital Culture Co., Ltd.
Tier 3FlowThroughput-Bound ConversionAttentionProduction
Dampskibsselskabet Norden A/S
Tier 3FlowThroughput-Bound ConversionProductionRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou TFC Optical Communication Co., Ltd.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth
NVIDIA Corporation
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth
Classys Inc.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit Growth